TD Cowen raised the firm’s price target on Ocular Therapeutix (OCUL) to $20 from $14 and keeps a Buy rating on the shares. The firm updated its model as they and key opinion leaders are highly optimistic about Axpaxli’s robust use in wAMD with a differentiated superiority label, and Cowen’s $1B peak estimate is conservative.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Optimistic Buy Rating for Ocular Therapeutix Driven by Axpaxli’s Market Potential in wAMD and NPDR
- Insider Moves: Ross, Carisma, Agree, Aehr, Ocular
- Ocular Therapeutix price target raised to $19 from $15 at H.C. Wainwright
- Ocular Therapeutix price target raised to $31 from $21 at Piper Sandler
- Ocular Therapeutix price target raised to $24 from $17 at Baird